Christopher Ryan Sullivan - 05 Oct 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer Zoltoski, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
05 Oct 2022
Net transactions value
$0
Form type
4
Filing time
07 Oct 2022, 16:01:47 UTC
Previous filing
10 Mar 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 05 Oct 2022 Common Stock 25,000 $3.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date.